OVID

Ovid Therapeutics Inc.

3.12 USD
-0.08 (-2.50%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Ovid Therapeutics Inc. stock is down -6.02% since 30 days ago. The next earnings date is Aug 2, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 7 June’s closed higher than May. 100% of analysts rate it a buy.

About Ovid Therapeutics Inc.

Ovid Therapeutics Inc. develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome. OV329, a GABA aminotransferase inhibitor, and OV350, a small molecule for treating epilepsies.